A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Ribociclib (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms NATALEE
- Sponsors Novartis
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 07 Oct 2018 Status changed from planning to not yet recruiting.
- 12 Jul 2018 New trial record